Suppr超能文献

抗血栓治疗在伴有心血管疾病的血友病患者中的应用:将严重出血风险最小化的最佳策略。

Debates Surrounding the Use of Antithrombotic Therapy in Hemophilic Patients with Cardiovascular Disease: Best Strategies to Minimize Severe Bleeding Risk.

机构信息

Department of Pathophysiology, University of Medicine and Pharmacy Grigore T. Popa, 700115 Iasi, Romania.

Department of Surgical Sciences, University of Medicine and Pharmacy Grigore T. Popa, 700115 Iasi, Romania.

出版信息

Int J Mol Sci. 2024 Jul 18;25(14):7845. doi: 10.3390/ijms25147845.

Abstract

Navigating through antithrombotic therapy in patients with both hemophilia and cardiovascular pathology presents a complex scenario with inherent challenges and opportunities. The presence of hemophilia, characterized by impaired blood clotting, adds a layer of complexity to the management of cardiovascular conditions requiring antiplatelet therapy and anticoagulation. Striking a delicate balance between the necessity for antithrombotic treatment to prevent cardiovascular events and the heightened risk of severe bleeding in individuals with hemophilia demands a nuanced and carefully considered approach. The challenges revolve around identifying an optimal therapeutic strategy that effectively mitigates cardiovascular risks without exacerbating bleeding tendencies. In hemophilic patients with cardiovascular disease, the decision to use antiplatelet therapy requires careful consideration of the individual's bleeding risk profile, considering factors such as the severity of hemophilia, history of bleeding episodes, and concurrent medications. The goal is to provide effective antithrombotic treatment while minimizing the potential for excessive bleeding complications. Conventional anticoagulants like warfarin pose difficulties due to their potential to increase the risk of bleeding. On the other hand, emerging options like novel direct oral anticoagulants (DOACs) present an opportunity, offering predictable pharmacokinetics and user-friendly administration. However, a comprehensive exploration of their safety and efficacy in hemophilic patients is imperative. Achieving the right equilibrium between preventing cardiovascular events and minimizing bleeding risk is pivotal in selecting the most effective therapeutic option for individuals with hemophilia and cardiovascular pathology. A multidisciplinary approach, integrating the expertise of hematologists and cardiologists, becomes essential to customize treatments and address the intricacies of this medical challenge.

摘要

在同时患有血友病和心血管疾病的患者中进行抗血栓治疗是一个复杂的情况,存在着固有挑战和机遇。血友病的存在,表现为血液凝结受损,为需要抗血小板治疗和抗凝治疗的心血管疾病的管理增加了一层复杂性。在需要抗血栓治疗以预防心血管事件与血友病患者严重出血风险增加之间取得微妙平衡,需要一种细致入微且经过深思熟虑的方法。挑战在于确定一种最佳的治疗策略,既能有效降低心血管风险,又不会加重出血倾向。在患有心血管疾病的血友病患者中,决定是否使用抗血小板治疗需要仔细考虑个体的出血风险状况,考虑因素包括血友病的严重程度、出血发作史和同时使用的药物。目标是提供有效的抗血栓治疗,同时最大限度地减少潜在的过度出血并发症。传统抗凝剂如华法林由于其增加出血风险的潜力而带来困难。另一方面,新型直接口服抗凝剂(DOACs)等新兴选择提供了机会,具有可预测的药代动力学和易于使用的给药方式。然而,必须全面探索它们在血友病患者中的安全性和疗效。在预防心血管事件和最小化出血风险之间取得正确平衡,对于为血友病和心血管疾病患者选择最有效的治疗方案至关重要。整合血液学家和心脏病专家的专业知识的多学科方法变得至关重要,以定制治疗方案并解决这一医学挑战的复杂性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcfd/11277257/8da3905d4a32/ijms-25-07845-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验